Bevacizumab-awwb

Bevacizumab-awwb is a biosimilar monoclonalDerived from a single source. In the context of cancer, the term is used in two ways: 1) to refer to the fact that tumors arise from a single damaged cell and 2) to describe the antibodies used in the treatment of cancer. antibodyAntibody molecules tightly bind to their targets (usually proteins) with great specificity. Antibody binding alerts the immune system to target the bound molecule for destruction. Specific antibodies can be made in the laboratory. that binds to and inhibits the activity of vascular endothelial growth factorA substance that stimulates cell division. Growth factors are usually small proteins or steroid hormones. They may be secreted by the same cells on which they act or by cells that reside in a different part of the body than the target cells. Some examples of growth factors include estrogen, a growth factor for breast cells, and VEGF, a growth factor that causes the development of blood vessels. Several different anti-cancer treatments are designed to inhibit the activity of growth factors. (VEGFVascular endothelial growth factor; a growth factor secreted by cells in the bone marrow that promotes the development of blood vessels (angiogenesis), leading to the growth of tumors.). This prevents the VEGF from interacting with its receptor on endothelial cells (lining of blood vessel). This, in turn, inhibits the formation of new blood vessels, which slows down the growth of the particular tissue. In essence, it kills tumors by cutting off their blood supply. 1